Abeona Therapeutics Incorporated (NASDAQ:ABEO) Shorted Shares Increased 21.44% After Market Selling

Abeona Therapeutics Inc

Abeona Therapeutics Incorporated (NASDAQ:ABEO) Shorted Shares Increased 21.44% After Market Selling

That suggests something of the likelihood of a short squeeze in shares of ABEO. Of those insider trades, 0 shares of Abeona Therapeutics Inc. were purchased and 0 shares were sold. Of those holders, 37 had increased positions amounting to 2.72 million shares, 26 had decreased positions amounting to 1.64 million shares, and 20 holders have a held position accounting for 11.04 million shares.

Taking a broader look at the analyst consensus, according to 6 analysts Abeona Therapeutics (NASDAQ:ABEO)'s price will reach at $23 during 52 weeks. The total number of shares traded in the last 12 months is 100,000. Abeona Therapeutics Inc (NASDAQ:ABEO) has risen 151.02% since October 11, 2016 and is uptrending. They expect $1.19 earnings per share, up 23.96% or $0.23 from last year's $0.96 per share. LADR's profit would be $39.88M giving it 9.59 P/E if the $0.36 EPS is correct. After $1.60 actual earnings per share reported by Marriott Vacations Worldwide Corp for the previous quarter, Wall Street now forecasts -25.63% negative EPS growth.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The company has market cap of $787.82 million. It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy for rare blood diseases. Of those analysts, 4 rate stock as a Strong Buy, 0 rate it as Hold, and just no analyst rates it as a Moderate Sell. Therefore 100% are positive.

According to Abeona Therapeutics Inc.'s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 38.23%. Jefferies maintained it with "Buy" rating and $21.0 target in Friday, September 22 report. The firm has "Buy" rating given on Tuesday, July 18 by Maxim Group. Jefferies maintained it with "Buy" rating and $27.0 target in Friday, October 6 report.

New Samsung image sensors could eliminate smartphone camera bumps
Samsung Electronics aims to bring ultra slim image sensors to smartphones and IoT devices with two new ISOCELL image sensors . The ISOCELL Fast 2L9 and Slim 2X7 are created to be slim and offer good performance in low-light conditions.

Among 8 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 8 have Buy rating, 0 Sell and 0 Hold. The rating was maintained by Cantor Fitzgerald on Monday, May 15 with "Buy".

There are 8 buy ratings on the stock.

Citigroup initiated its coverage for Abeona Therapeutics (NASDAQ:ABEO), this morning Tuesday, 10 October. Wellington Management Group LLP grew its holdings in shares of Abeona Therapeutics by 17.4% during the 1st quarter. The firm has "Buy" rating by Rodman & Renshaw given on Wednesday, April 20.

Investors sentiment decreased to 0.79 in Q2 2017. Its down 0.66, from 2.63 in 2017Q1. 111 funds opened positions while 598 raised stakes. Private Advisor Group, LLC now controls 10,230 shares with a value of $94,000. Similar statistics are true for the second largest owner, Adage Capital Partners Gp, L.L.C., which owns 1,950,000 shares of the stock are valued at $34.13 million. Howe And Rusling Inc reported 351 shares. The company's shares were assimilated at $5.5 per share worth to an investment of some $110,000 on account of Wider Todd. Allianz Asset Management Gmbh now owns 122,692 shares worth $785,000. Paradigm Advsr Limited Co holds 2.75% in General Electric Company (NYSE:GE) or 200,970 shares. Advisors Lp, which now holds $29.48 million worth of this stock and that ownership represents almost 3.9% of its market capitalization. The firm has "Market Perform" rating given on Friday, February 19 by Wells Fargo. The stock's 52-week range is $4.05 to $18.90, and its 3-month range is $ to $. On September 15 analysts at RBC Capital issued its first research report on the stock by announcing an initial rating of "Outperform". Maxim Group maintained Abeona Therapeutics Inc (NASDAQ:ABEO) rating on Wednesday, August 16.

Latest News